Contact informationPlease contact Karolina Cyll for more information
Prostate cancer is known for being especially heterogeneous, meaning areas within the same tumors display different genotypes.
These areas will be affected differently by medications and curative measures, which poses a great challenge to treatment. If one core biopsy from a prostate tumor is analyzed, there is a strong probability that it is not representative of the entire disease.
Both inter- and intra-tumor heterogeneity is studied by analyzing samples from all tumor blocks from each patient. DNA ploidy analyses show that only 20% of the patients have the same DNA ploidy classification throughout the tumor. Samples from patients with advanced disease show a higher degree of heterogeneity than those with more indolent tumors. This tells us that although DNA ploidy is a strong cancer marker, one sample per patient is not sufficient and we recommend that a minimum of three blocks per patient must be analyzed to determine the ploidy classification.
We examine the heterogeneity in prostate cancer both between patients, and within individual patients. DNA ploidy analyses are combined with Nucleotyping, FISH and cancer-related gene expression with immunohistochemistry and NanoString (mRNA) analyses.